Literature DB >> 24631501

Comparing clinical features of young onset, middle onset and late onset Parkinson's disease.

Raja Mehanna1, Suzanne Moore2, J Gabriel Hou2, Aliya I Sarwar2, Eugene C Lai3.   

Abstract

BACKGROUND: Parkinson's disease (PD) affects 1-2% of the population over 65 years. There is evidence that the clinical features differ with age at symptom onset, but published information is scarce.
METHODS: We reviewed the charts of 593 PD patients and divided them into young onset (≤49 years), middle onset (50-69 years) and late onset (≥70 years) groups. Data collected included age at symptom onset, year of onset, family history of Parkinson's disease in first and second degree relatives, predominant first symptom, first anti parkinsonian medication prescribed, frequency of levodopa-induced dyskinesia, therapy related dystonia, therapy related gastrointestinal side effects, hallucination, dementia, depression and apathy.
RESULTS: The middle onset was the largest group (51%), followed by the late onset (39%) and the young onset (10%) groups. Young onset patients had a more frequent family history of Parkinson's disease and a longer survival. Symptoms other than tremor were more frequent as the initial symptom of the young onset group, and the frequency of tremor as the first symptom increased with advancing age at onset. Depression was more frequent in the young onset group. The frequency of treatment related dyskinesia or dystonia decreased with advancing age at onset.
CONCLUSION: We have identified specific clinical differences in Parkinson's disease related to the patient's age at onset and added to the existing knowledge of the variability of disease presentation. We suggest an age of onset of 49 years or less for the definition of young onset PD.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Age at onset; Parkinson; Young onset

Mesh:

Substances:

Year:  2014        PMID: 24631501     DOI: 10.1016/j.parkreldis.2014.02.013

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  35 in total

1.  Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts.

Authors:  Joanna A Korecka; Ria Thomas; Dan P Christensen; Anthony J Hinrich; Eliza J Ferrari; Simon A Levy; Michelle L Hastings; Penelope J Hallett; Ole Isacson
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

2.  Real-world pharmacological treatment patterns of patients with young-onset Parkinson's disease in Japan: a medical claims database analysis.

Authors:  Sachiko Kasamo; Masato Takeuchi; Masashi Ikuno; Yohei Kawasaki; Shiro Tanaka; Ryosuke Takahashi; Koji Kawakami
Journal:  J Neurol       Date:  2019-05-10       Impact factor: 4.849

3.  Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.

Authors:  Alessandra Nicoletti; Giovanni Mostile; Giuseppe Nicoletti; Gennarina Arabia; Giovanni Iliceto; Paolo Lamberti; Roberto Marconi; Letterio Morgante; Paolo Barone; Aldo Quattrone; Mario Zappia
Journal:  J Neurol       Date:  2016-03-10       Impact factor: 4.849

Review 4.  Population Base Rates and Disease Course of Common Psychiatric and Neurodegenerative Disorders.

Authors:  Katherine A Kitchen Andren; Nicolette M Gabel; Julija Stelmokas; Alyson M Rich; Linas A Bieliauskas
Journal:  Neuropsychol Rev       Date:  2017-09-22       Impact factor: 7.444

Review 5.  Age Cutoff for Early-Onset Parkinson's Disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson's Disease.

Authors:  Raja Mehanna; Katarzyna Smilowska; Jori Fleisher; Bart Post; Taku Hatano; Maria Elisa Pimentel Piemonte; Kishore Raj Kumar; Victor McConvey; Baorong Zhang; Eng-King Tan; Rodolfo Savica
Journal:  Mov Disord Clin Pract       Date:  2022-09-10

Review 6.  Therapy of Parkinson's Disease Subtypes.

Authors:  Connie Marras; K Ray Chaudhuri; Nataliya Titova; Tiago A Mestre
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

Review 7.  Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.

Authors:  Dhanya Vijayakumar; Joseph Jankovic
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

8.  Sex differences in Parkinson's disease presentation and progression.

Authors:  Danielle S Abraham; Ann L Gruber-Baldini; Laurence S Magder; Patrick F McArdle; Sarah E Tom; Erik Barr; Katrina Schrader; Lisa M Shulman
Journal:  Parkinsonism Relat Disord       Date:  2019-10-23       Impact factor: 4.891

9.  Age at onset and Parkinson disease phenotype.

Authors:  Gennaro Pagano; Nicola Ferrara; David J Brooks; Nicola Pavese
Journal:  Neurology       Date:  2016-02-10       Impact factor: 9.910

10.  Utility of Imaging of Nigrosome-1 on 3T MRI and Its Comparison with 18F-DOPA PET in the Diagnosis of Idiopathic Parkinson Disease and Atypical Parkinsonism.

Authors:  Heena Kathuria; Sahil Mehta; Chirag K Ahuja; Kamalesh Chakravarty; Sucharita Ray; Bhagwant Rai Mittal; Paramjeet Singh; Vivek Lal
Journal:  Mov Disord Clin Pract       Date:  2020-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.